Martin Rexroad has been appointed senior vice president of Human Resources at PTC Therapeutics, Inc. and R.A. Session II has been named vice president of Corporate Development, both reporting to Claudia Hirawat, president of PTC Therapeutics, Inc. Also, Jay Barth has been promoted to senior vice president of Clinical Development.
Mr. Rexroad has more than 25 years of experience across all areas of Human Resources in multiple industries and stages of development. Prior to joining the company, Mr. Rexroad served as vice president of Human Resources at Terumo Medical Corp. He also served as vice president of Human Resources at Osteotech, Inc. and held various positions in other industries including New York Life Insurance Co. and Altria Corporate Services, Inc.
R.A. Session II returns to PTC to work cross-functionally in corporate strategy, commercial development and finance. Prior to joining PTC, Mr. Session was senior director, Strategic Planning & Finance at Reata Pharmaceuticals, where he led strategic analytics, valuation analysis, market access, pricing and long-range planning. Prior to Reata, Mr. Session served as associate director Strategic Planning & Finance at PTC from 2008 to 2010. Mr. Session has also held various positions in strategic planning, drug development, and commercialization at AstraZeneca and Johnson & Johnson.
Dr. Jay Barth leads PTC's clinical team and oversees all clinical trials at the company. Dr. Barth joined PTC in 2009 as executive director of Clinical Development and was promoted to vice president in 2011. Prior to joining PTC, Dr. Barth was executive director of Clinical Research at Merck and served as vice president, Clinical Research and Medical Affairs at Altana Pharma US, Inc.
"It is my pleasure to welcome Mr. Rexroad and Mr. Session to PTC as we expand the breadth of our management team. Mr. Rexroad's extensive experience will play an integral role in our ability to cultivate the human capital that enables our advancement as an organization and Mr. Session's experience in commercialization and finance will be an asset as we outline our strategy for growth," said Ms. Hirawat. "In addition, we are delighted to announce the promotion of Dr. Jay Barth. Since joining PTC, Dr. Barth has made significant contributions to the clinical development programs, corporate strategy and was an instrumental part of our recent IPO. Dr. Barth is an asset to our team and a cherished colleague."